Obesity Featured Articles
-
Autoimmune Drugs For Women: What To Bring To The Clinic
9/24/2026
Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise.
-
The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect
9/23/2026
Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.
-
Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us
9/22/2026
Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.
-
Lessons From The Front Lines: Navigating The Operational Challenges Of Next-Generation ADC Trials
9/22/2026
See how smarter protocol design and real-time safety monitoring can ease patient burden and keep next-gen ADC oncology trials on track.
-
The U.S. Clinical Trial Recruiting Pipeline Report – August 2026
9/22/2026
This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from July and August.
-
How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued
9/22/2026
Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.
-
Resensitizing Treatment-Resistant Cancer Holds Promise Over Replacing Once-Efficacious Therapies
9/21/2026
John Yu, MD, of Kairos Pharma, explains why reversing treatment resistance could extend the life of proven cancer therapies and improve patient outcomes.
-
AI, Open Source, & the Future of Biostatistics
9/18/2026
AI and open-source tools are changing statistical programming. Learn how to validate, govern, and apply them without sacrificing the accuracy and oversight clinical research demands.
-
Why Oncology Programs Can't Rely On An Inside View Alone
9/18/2026
Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
-
In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies
9/17/2026
I review 10 of the FDA’s guidances spanning the last 12 months, all of which aid cell and gene therapy companies to assure safety and efficacy of these medicines.